ASTRAZENECA PLC (AZN)
ASTRAZENECA PLC (AZN) is a multinational biopharmaceutical company developing and commercializing prescription medicines across multiple therapeutic areas including oncology, cardiovascular, renal, respiratory, and immunology. Based in Cambridge, United Kingdom, the company operates research, development, manufacturing, and distribution operations globally.
What the company does
AstraZeneca discovers, develops, manufactures, and markets prescription pharmaceuticals for patients worldwide. The company operates across four primary therapeutic areas: oncology (addressing various cancers), cardiovascular and renal disease, respiratory and immunology (including asthma and chronic obstructive pulmonary disease), and specialized medicines. Its product portfolio includes both primary care and specialty care offerings delivered through retail pharmacies, hospital systems, and healthcare providers.
How it makes money
Revenue flows from sales of branded prescription drugs to healthcare systems, hospitals, pharmacy chains, and patients via insurance or direct purchase. The company also generates revenue from licensing agreements with other pharmaceutical manufacturers and from milestone payments in drug development partnerships. Cost of goods sold includes manufacturing, distribution, and marketing expenses. Research and development represents a significant operating expense, as maintaining a pipeline of new drug candidates requires continuous investment in clinical trials and laboratory research across multiple geographic markets.
Where it sits in its industry
AstraZeneca competes with other large integrated biopharmaceutical companies including Pfizer, Merck & Co., Johnson & Johnson, and others developing therapies in similar disease areas. The company has established a global presence with commercial operations in North America, Europe, and Asia-Pacific regions. Competition in pharmaceuticals centers on patent protection, clinical efficacy data, regulatory approval timelines, manufacturing scale, pricing power, and the ability to successfully transition revenues when key products lose exclusivity. Market dynamics favor companies with diverse pipelines, efficient clinical development, and strong relationships with healthcare providers and payers.
How to research it
Start with the company’s SEC filings, particularly the annual Form 10-K and quarterly Form 10-Q reports, which detail pipeline status, revenue by geography and therapeutic area, patent expiration schedules, regulatory proceedings, and competitive positioning. Investor relations materials on the company website provide updates on clinical trial results, regulatory submissions, and strategic partnerships. Industry publications covering biopharmaceutical development and healthcare policy offer context on market trends, pricing pressures, and competitive landscape shifts. The company also discloses material events and updates through SEC filings and public announcements, which should be consulted for material developments in drug approvals or product performance.